Literature DB >> 21768959

Factors determining how early adopter physicians use buprenorphine in treatment.

Sharon Reif1, Cindy Parks Thomas, Stanley S Wallack.   

Abstract

Since October 2002, physicians have been able to prescribe buprenorphine to treat opiate dependence. We examined how physicians who prescribe buprenorphine are using it in practice to determine how well buprenorphine has been adopted as a realistic and effective treatment option, with the ultimate goal of improved access to opiate addiction treatment. Most prescribing physicians offer buprenorphine in various ways, ranging from detoxification to extended maintenance, including transfer from methadone and treatment of chronic pain. On average, physicians write 16 prescriptions monthly, one-third of which are for new patients. The average buprenorphine prescriber has treated 72 buprenorphine patients to date. Two-thirds prescribe for both detoxification and maintenance, allowing flexibility to meet patient needs; 19% prescribe only for detoxification, and 14% only for maintenance. Prescribing patterns are associated with experience treating addictions, patient mix, and available resources. Physicians who prescribe for detoxification only should recognize that additional resources are not necessary for maintenance, the recommended treatment for opiate addiction. Physicians who prescribe for maintenance only would benefit from linkages with physicians or facilities that offer buprenorphine detoxification, so patients who refuse maintenance may still be treated. With additional network development and support for physicians, access to buprenorphine treatment can be improved.

Entities:  

Year:  2007        PMID: 21768959     DOI: 10.1097/ADM.0b013e31814c3fa8

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  11 in total

1.  Timing of buprenorphine adoption by privately funded substance abuse treatment programs: the role of institutional and resource-based interorganizational linkages.

Authors:  Sarah A Savage; Amanda J Abraham; Hannah K Knudsen; Tanja C Rothrauff; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2011-08-09

2.  Adoption and implementation of medications in addiction treatment programs.

Authors:  Hannah K Knudsen; Amanda J Abraham; Paul M Roman
Journal:  J Addict Med       Date:  2011-03       Impact factor: 3.702

3.  Physicians as Mediators of Health Policy: Acceptance of Medicaid in the Context of Buprenorphine Treatment.

Authors:  Hannah K Knudsen; Jamie L Studts
Journal:  J Behav Health Serv Res       Date:  2019-01       Impact factor: 1.505

4.  Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs.

Authors:  Christina M Andrews; Thomas A D'Aunno; Harold A Pollack; Peter D Friedmann
Journal:  Med Care Res Rev       Date:  2013-09-18       Impact factor: 3.929

5.  Perceived Impacts of the Affordable Care Act: Perspectives of Buprenorphine Prescribers.

Authors:  Hannah K Knudsen; Jamie L Studts
Journal:  J Psychoactive Drugs       Date:  2017-03-15

6.  The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis.

Authors:  Hannah K Knudsen
Journal:  J Stud Alcohol Drugs       Date:  2015-07       Impact factor: 2.582

7.  A qualitative study of the adoption of buprenorphine for opioid addiction treatment.

Authors:  Carla A Green; Dennis McCarty; Jennifer Mertens; Frances L Lynch; Anadam Hilde; Alison Firemark; Constance M Weisner; David Pating; Bradley M Anderson
Journal:  J Subst Abuse Treat       Date:  2013-10-23

8.  The effect of a "universal antiretroviral therapy" recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/μL in a public health setting.

Authors:  Elvin H Geng; C Bradley Hare; James O Kahn; Vivek Jain; Tracy Van Nunnery; Katerina A Christopoulos; Steven G Deeks; Monica Gandhi; Diane V Havlir
Journal:  Clin Infect Dis       Date:  2012-09-05       Impact factor: 9.079

9.  Patient decision aid for medication treatment for opioid use disorder (PtDA-MOUD): Rationale, methodology, and preliminary results.

Authors:  Larissa J Mooney; Jonathan Valdez; Sarah J Cousins; Caroline Yoo; Yuhui Zhu; Yih-Ing Hser
Journal:  J Subst Abuse Treat       Date:  2019-10-24

10.  Access to Addiction Pharmacotherapy in Private Health Plans.

Authors:  Sharon Reif; Constance M Horgan; Dominic Hodgkin; Ann-Marie Matteucci; Timothy B Creedon; Maureen T Stewart
Journal:  J Subst Abuse Treat       Date:  2016-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.